ClassID:

95637

C07D515/18 - CPC Classification

Classification description:

Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or  -  in which the condensed system contains three hetero rings Bridged systems

Recent Application in this class:
#1
20260078133
2026-03-19

RAS INHIBITORS

#2
20260008786
2026-01-08

MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF

#3
20260008785
2026-01-08

MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF

#4
20250197422
2025-06-19

MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF

#5
20250197420
2025-06-19

MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF

#6
20240317777
2024-09-26

NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS

#7
20240190893
2024-06-13

MACROCYCLIC 1,3-BRIDGED 6-CHLORO-7-PYRAZOL-4-YL-1 H-INDOLE-2-CARBOXYLATE AND 6-CHLORO-7-PYRIMIDIN-5-YL-1H-INDOLE-2-CARBOXYLATE DERIVATIVES AS MCL-1 INHIBITORS FOR THE TREATMENT OF CANCER

#8
20240067651
2024-02-29

PRODRUGS OF MYELOPEROXIDASE INHIBITORS

#9
20230416275
2023-12-28

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

#10
20230382924
2023-11-30

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

#11
20230374038
2023-11-23

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

#12
20230365587
2023-11-16

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

#13
20230257396
2023-08-17

MACROCYCLES AND THEIR USE

#14
20230145835
2023-05-11

Modulators of Alpha-4-beta-7 Integrin and MAdCAM

#15
20230097678
2023-03-30

NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

#16
20220389031
2022-12-08

MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS

#17
20220241291
2022-08-04

OXYGEN LINKED PYRIMIDINE DERIVATIVES

#18
20220071971
2022-03-10

MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE

#19
20200071339
2020-03-05

Oxygen linked pyrimidine derivatives

#20
20180230168
2018-08-16

Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors

#21
20170226130
2017-08-10

Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors

#22
20160024113
2016-01-28

Macrocyclic salt-inducible kinase inhibitors

#23
20150051183
2015-02-19

Conformationally constrained, fully synthetic macrocyclic compounds

#24
20140107101
2014-04-17

Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

#25
20130296330
2013-11-07

MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS

#26
20130172338
2013-07-04

Oxygen linked pyrimidine derivatives

#27
20130035341
2013-02-07

Macrocyclic integrase inhibitors

#28
20120196855
2012-08-02

Oxygen linked pyrimidine derivatives

#29
20120172367
2012-07-05

Macrocyclic integrase inhibitors

#30
20120142680
2012-06-07

Heteroalkyl linked pyrimidine derivatives

#31
20110105473
2011-05-05

Macrocyclic indole derivatives useful as hepatitis C virus inhibitors

#32
20110082182
2011-04-07

THERAPEUTIC ANTIVIRAL PEPTIDES

#33
20100216987
2010-08-26

Synthesis of naturally occuring ecteinascidins and related compounds

#34
20100076046
2010-03-25

Antiviral indoles

#35
20090258886
2009-10-15

Heteroalkyl linked pyrimidine derivatives

#36
20090163507
2009-06-25

Synthesis of naturally occurring ecteinascidins and related compounds

#37
20090137597
2009-05-28

Novel quinoxalinone derivatives

#38
20090075999
2009-03-19

Oxygen linked pyrimidine derivatives

#39
20090048239
2009-02-19

Therapeutic compounds

#40
20070093658
2007-04-26

Synthesis of naturally occurring ecteinascidins and related compounds

#41
20060019959
2006-01-26

Quinoxalinone derivatives